Compare Solaredge Technologies Inc (SEDG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaredge Technologies Inc vs TG Therapeutics Inc — how do they compare? Solaredge Technologies Inc trades at $32.08 (market cap $2.00B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 4.1× Solaredge Technologies Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Solaredge Technologies Inc for 34 Days and TG Therapeutics Inc for 16 Days on average.
| SEDG | TGTX | |
|---|---|---|
Market Cap | $2.00B | $8.16B |
Volume | 2,739,860 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $78.51 | $59.06 |
52-Week Low | $28.47 | $26.94 |
Typical Hold Time | 34 Days | 16 Days |
Enterprise Value | $1.86B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SolarEdge Technologies (SEDG) trades at $32.21, down 2.86% on the day, amid a bearish technical signal and mixed earnings performance. The company reported a net loss of $405.45M in 2025, with negative profit margins, though revenue grew to $1.18B. Recent news highlights legal investigations and volatility driven by solar sector pressures and new AI data center initiatives announced in September 2026.
The outlook remains cautious due to persistent losses and high debt, but analyst consensus suggests moderate upside to a $37.75 price target. Key risks include ongoing legal scrutiny, competitive pressures, and reliance on solar market recovery. Investment appeal hinges on execution of growth targets and margin improvement.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
